Cure Ventures, a Boston-based life sciences venture capital firm specializing in company formation around groundbreaking curative technologies, announced Tuesday the successful close of its inaugural fund – Cure Ventures Fund I, L.P., at its targeted hard-cap of $350 million in capital commitments. The syndicate comprised both U.S.- and international investors who supported the fund launch led by VC veterans Richard Lim, David Fallace and Lou Tartaglia.
The focus is on early-stage investments in life science and biotechnology with an emphasis on new therapeutics where embedded Cure operators will work alongside portfolio company founders to drive day-to-day decision making processes for optimal results.
“Biopharma venture capital requires rigorous diligence as well as patience,” said Lim.”We are committed to partnering closely with founders through sweat equity so that we can collaborate effectively when operationalizing our investments.”
This successful close comes amidst headwinds buffeting the local life sciences market resulting from difficulty securing funding for growth needs among private companies according to reports earlier this year . Pictured (from left) are Cure Venture’s founding members: Lou Tartaglia, Richard Lim and David Fallace
